- Home
- EIC vs VALN Comparison
EIC vs VALN Comparison
Compare EIC & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- VALN
- Stock Information
- Founded
- EIC N/A
- VALN 2012
- Country
- EIC United States
- VALN France
- Employees
- EIC N/A
- VALN N/A
- Industry
- EIC Finance/Investors Services
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EIC Finance
- VALN Health Care
- Exchange
- EIC Nasdaq
- VALN Nasdaq
- Market Cap
- EIC 287.1M
- VALN 332.0M
- IPO Year
- EIC 2019
- VALN 2021
- Fundamental
- Price
- EIC $15.37
- VALN $4.03
- Analyst Decision
- EIC
- VALN Strong Buy
- Analyst Count
- EIC 0
- VALN 2
- Target Price
- EIC N/A
- VALN $18.50
- AVG Volume (30 Days)
- EIC 116.0K
- VALN 44.1K
- Earning Date
- EIC 11-14-2023
- VALN 11-07-2024
- Dividend Yield
- EIC 13.63%
- VALN N/A
- EPS Growth
- EIC N/A
- VALN N/A
- EPS
- EIC 0.80
- VALN N/A
- Revenue
- EIC N/A
- VALN $176,817,979.00
- Revenue This Year
- EIC N/A
- VALN $24.30
- Revenue Next Year
- EIC N/A
- VALN $16.05
- P/E Ratio
- EIC $20.31
- VALN N/A
- Revenue Growth
- EIC N/A
- VALN N/A
- 52 Week Low
- EIC $13.00
- VALN $3.62
- 52 Week High
- EIC $16.48
- VALN $10.76
- Technical
- Relative Strength Index (RSI)
- EIC 35.79
- VALN 43.67
- Support Level
- EIC $15.11
- VALN $3.62
- Resistance Level
- EIC $15.35
- VALN $4.38
- Average True Range (ATR)
- EIC 0.16
- VALN 0.22
- MACD
- EIC -0.04
- VALN 0.06
- Stochastic Oscillator
- EIC 20.83
- VALN 53.29
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.